Leerink Swann downgraded shares of Juno Therapeutics (NASDAQ:JUNO) from an outperform rating to a market perform rating in a research note issued to investors on Tuesday, Marketbeat.com reports. Leerink Swann currently has $87.00 price objective on the biopharmaceutical company’s stock, up from their prior price objective of $56.00.

JUNO has been the topic of several other reports. SunTrust Banks upgraded shares of Juno Therapeutics from a hold rating to a buy rating in a research report on Thursday, November 2nd. Morgan Stanley reiterated an equal weight rating and set a $43.00 target price (up from $27.00) on shares of Juno Therapeutics in a research report on Friday, October 6th. Cowen reiterated a buy rating and set a $49.00 target price on shares of Juno Therapeutics in a research report on Friday, October 27th. Raymond James Financial lifted their target price on shares of Juno Therapeutics from $45.00 to $61.00 and gave the stock an outperform rating in a research report on Friday, November 3rd. Finally, Wedbush reiterated an outperform rating and set a $64.00 target price (up from $42.00) on shares of Juno Therapeutics in a research report on Thursday, November 2nd. Two investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and three have assigned a buy rating to the company’s stock. The company has a consensus rating of Hold and a consensus price target of $51.20.

Shares of Juno Therapeutics (NASDAQ JUNO) opened at $85.72 on Tuesday. The company has a current ratio of 4.77, a quick ratio of 4.77 and a debt-to-equity ratio of 0.01. Juno Therapeutics has a 1 year low of $19.33 and a 1 year high of $86.28. The company has a market cap of $9,790.00, a P/E ratio of -25.29 and a beta of 2.32.

Juno Therapeutics (NASDAQ:JUNO) last posted its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) EPS for the quarter, topping the consensus estimate of ($0.80) by $0.07. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business had revenue of $44.80 million for the quarter, compared to the consensus estimate of $18.12 million. During the same period last year, the company earned ($0.57) EPS. The firm’s revenue was up 115.4% compared to the same quarter last year. analysts predict that Juno Therapeutics will post -4.02 earnings per share for the current year.

In other Juno Therapeutics news, EVP Robert Azelby sold 102,539 shares of the firm’s stock in a transaction that occurred on Monday, January 22nd. The shares were sold at an average price of $86.25, for a total transaction of $8,843,988.75. Following the completion of the transaction, the executive vice president now owns 173,371 shares in the company, valued at approximately $14,953,248.75. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CFO Steve Harr sold 8,750 shares of the firm’s stock in a transaction that occurred on Thursday, December 21st. The stock was sold at an average price of $44.76, for a total transaction of $391,650.00. Following the transaction, the chief financial officer now owns 772,082 shares of the company’s stock, valued at approximately $34,558,390.32. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 467,876 shares of company stock valued at $26,384,487. Company insiders own 15.08% of the company’s stock.

A number of institutional investors have recently added to or reduced their stakes in JUNO. Capital International Investors bought a new stake in shares of Juno Therapeutics in the 3rd quarter valued at $256,339,000. Redmile Group LLC bought a new stake in shares of Juno Therapeutics in the 2nd quarter valued at $66,344,000. Jennison Associates LLC increased its stake in shares of Juno Therapeutics by 162.0% in the 3rd quarter. Jennison Associates LLC now owns 1,988,708 shares of the biopharmaceutical company’s stock valued at $89,213,000 after acquiring an additional 1,229,622 shares in the last quarter. Orbimed Advisors LLC increased its stake in shares of Juno Therapeutics by 123.1% in the 3rd quarter. Orbimed Advisors LLC now owns 2,041,608 shares of the biopharmaceutical company’s stock valued at $91,587,000 after acquiring an additional 1,126,400 shares in the last quarter. Finally, Capital Guardian Trust Co. bought a new stake in shares of Juno Therapeutics in the 3rd quarter valued at $37,400,000. Hedge funds and other institutional investors own 69.96% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “Leerink Swann Downgrades Juno Therapeutics (JUNO) to Market Perform” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this story on another website, it was illegally stolen and reposted in violation of United States and international copyright law. The correct version of this story can be accessed at https://www.thecerbatgem.com/2018/01/27/leerink-swann-downgrades-juno-therapeutics-juno-to-market-perform.html.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

Receive News & Ratings for Juno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Juno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.